ReShape Lifesciences (NASDAQ:RSLS) Announces Earnings Results, Beats Estimates By $2.17 EPS

ReShape Lifesciences (NASDAQ:RSLS) announced its earnings results on Friday. The medical device company reported ($1.89) EPS for the quarter, topping the consensus estimate of ($4.06) by $2.17, Zacks reports. ReShape Lifesciences had a negative net margin of 86.36% and a negative return on equity of 179.83%. The firm had revenue of $1.81 million for the quarter, compared to the consensus estimate of $3.17 million.

ReShape Lifesciences Price Performance

NASDAQ RSLS opened at $0.46 on Friday. The stock has a 50-day simple moving average of $1.59 and a 200 day simple moving average of $3.99. ReShape Lifesciences has a twelve month low of $0.34 and a twelve month high of $29.00.

ReShape Lifesciences Company Profile

ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.